Switch to:

Denali Therapeutics Debt-to-Equity

: 0.16 (As of Sep. 2019)
View and export this data going back to 2017. Start your Free Trial

Denali Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was $0.0 Mil. Denali Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was $69.9 Mil. Denali Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2019 was $438.2 Mil. Denali Therapeutics's debt to equity for the quarter that ended in Sep. 2019 was 0.16.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

NAS:DNLI' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.14   Max: 0.16
Current: 0.16

0.14
0.16

During the past 4 years, the highest Debt-to-Equity Ratio of Denali Therapeutics was 0.16. The lowest was 0.14. And the median was 0.15.

NAS:DNLI's Debt-to-Equity is ranked lower than
53% of the 859 Companies
in the Biotechnology industry.

( Industry Median: 0.12 vs. NAS:DNLI: 0.16 )

Denali Therapeutics Debt-to-Equity Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Denali Therapeutics Annual Data
Dec15 Dec16 Dec17 Dec18
Debt-to-Equity 0.00 0.00 0.00 0.00

Denali Therapeutics Quarterly Data
Dec15 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Debt-to-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.14 0.15 0.16

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Denali Therapeutics Debt-to-Equity Distribution

* The bar in red indicates where Denali Therapeutics's Debt-to-Equity falls into.



Denali Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Denali Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Denali Therapeutics's Debt to Equity Ratio for the quarter that ended in Sep. 2019 is calculated as

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Denali Therapeutics  (NAS:DNLI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Denali Therapeutics Debt-to-Equity Related Terms


Denali Therapeutics Debt-to-Equity Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)